Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy

被引:5
作者
Moise, PA [1 ]
Schentag, JJ [1 ]
机构
[1] Millard Fillmore Hosp, Clin Pharmacokinet Lab, Buffalo, NY 14209 USA
关键词
D O I
10.1097/00001432-199812000-00005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Despite the advances in pharmacokinetic and pharmacodynamic modelling, there is still much more to gain from this concept. The use of pharmacokinetic and pharmacodynamic modelling in vitro, in animal and in human models has confirmed that an index, such as peak concentration divided by the minimum inhibitory concentration (C-max/MIC), the area under the curve divided by the minimum inhibitory concentration (AUC/MIC) and time above the minimum inhibitory concentration (T>(MIC)), may be used as an aid to understanding better the variability between patients who receive similar antibiotic dosage regimens but have dissimilar outcomes. Efforts to find the optimal pharmacokinetic or pharmacodynamic index predictive of response is crucial to identify targets that will ensure efficacy and for the prediction of failure. Curr Opin infect Dis 11:673-680. (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:673 / 680
页数:8
相关论文
共 42 条
[31]   Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens [J].
Occhipinti, DJ ;
Pendland, SL ;
Schoonover, LL ;
Rypins, EB ;
Danziger, LH ;
Rodvold, KA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2511-2517
[32]   PHARMACOECONOMIC ANALYSIS OF CEFMENOXIME DUAL INDIVIDUALIZATION IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA [J].
PALADINO, JA ;
FELL, RE .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (03) :384-389
[33]   Pharmacodynamics of levofloxacin - A new paradigm for early clinical trials [J].
Preston, SL ;
Drusano, GL ;
Berman, AL ;
Fowler, CL ;
Chow, AT ;
Dornseif, B ;
Reichl, V ;
Natarajan, J ;
Corrado, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (02) :125-129
[34]   BETA-LACTAM RESISTANCE IN GRAM-NEGATIVE BACTERIA - GLOBAL TRENDS AND CLINICAL IMPACT [J].
SANDERS, CC ;
SANDERS, WE .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (05) :824-839
[35]  
Schentag J J, 1997, Semin Respir Infect, V12, P278
[36]   AUIC - The universal parameter within the constraint of a reasonable dosing interval [J].
Schentag, JJ ;
Nix, DE ;
Forrest, A ;
Adelman, MH .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (09) :1029-1031
[37]   MATHEMATICAL EXAMINATION OF DUAL INDIVIDUALIZATION PRINCIPLES (I) - RELATIONSHIPS BETWEEN AUC ABOVE MIC AND AREA UNDER THE INHIBITORY CURVE FOR CEFMENOXIME, CIPROFLOXACIN, AND TOBRAMYCIN [J].
SCHENTAG, JJ ;
NIX, DE ;
ADELMAN, MH .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (10) :1050-1057
[38]   ROLE FOR DUAL INDIVIDUALIZATION WITH CEFMENOXIME [J].
SCHENTAG, JJ ;
SMITH, IL ;
SWANSON, DJ ;
DEANGELIS, C ;
FRACASSO, JE ;
VARI, A ;
VANCE, JW .
AMERICAN JOURNAL OF MEDICINE, 1984, 77 (6A) :43-50
[39]   CEFMENOXIME EFFICACY, SAFETY, AND PHARMACOKINETICS IN CRITICAL CARE PATIENTS WITH NOSOCOMIAL PNEUMONIA [J].
SCHENTAG, JJ ;
REITBERG, DP ;
CUMBO, TJ .
AMERICAN JOURNAL OF MEDICINE, 1984, 77 (6A) :34-42
[40]   Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy [J].
Thomas, JK ;
Forrest, A ;
Bhavnani, SM ;
Hyatt, JM ;
Cheng, A ;
Ballow, CH ;
Schentag, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :521-527